Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug–Associated Thrombosis Among Patients With Multiple Myeloma

Journal of the National Comprehensive Cancer Network : JNCCN - United States
doi 10.6004/jnccn.2018.7273
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Harborside Press, LLC

Related search

Derivation and Validation of a Prediction Model for Risk Stratification of Post-Thrombotic Syndrome in Elderly Patients With a First Deep Vein Thrombosis

Thrombosis and Haemostasis
Hematology
2018English

Validation of Risk Assessment Models for Venous Thrombosis in Hospitalized Medical Patients

Research and Practice in Thrombosis and Haemostasis
2019English

Microparticle-Associated Tissue Factor Activity and Venous Thrombosis in Multiple Myeloma

Thrombosis and Haemostasis
Hematology
2011English

Geriatric Assessment in Multiple Myeloma Patients: Validation of the International Myeloma Working Group (IMWG) Score and Comparison With Other Common Comorbidity Scores

Haematologica
Hematology
2016English

Emerging Treatments for Multiple Myeloma: Beyond Immunomodulatory Drugs and Bortezomib

Seminars in Hematology
Hematology
2009English

A High-Risk Signature for Patients With Multiple Myeloma Established From the Molecular Classification of Human Myeloma Cell Lines

Haematologica
Hematology
2010English

Is Edentulism Associated With Lower Bacteremia and Transplant-Associated Toxicities in Patients With Multiple Myeloma?

Biology of Blood and Marrow Transplantation
TransplantationHematology
2013English

A Validation, With New Clinical Applicability, of a Clinical-Genetic Risk Model That Predicts Thrombosis With High Sensitivity in Patients With Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Infections in Hospitalised Patients With Multiple Myeloma: Main Characteristics and Risk Factors

Turkish Journal of Haematology
Hematology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy